Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid
- 27 May 2020
- journal article
- letter
- Published by Elsevier BV in Medical Hypotheses
- Vol. 143, 109891
- https://doi.org/10.1016/j.mehy.2020.109891
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Valproate-Associated Isolated Serum Creatine Kinase ElevationClinical Journal of Sport Medicine, 2020
- Virtual Screening and Molecular Dynamics Simulation Suggest Valproic Acid Co-A could Bind to SARS-CoV2 RNA Depended RNA PolymerasePreprints.org, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injuryThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Inhibition of herpes virus infection in oligodendrocyte cultured cells by valproic acidVirus Research, 2016
- Levetiracetam but not valproate inhibits function of CD8+ T lymphocytesSeizure, 2013
- Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κBBrain Research, 2000